Cipla, a drug major, is making significant investments in the highly competitive diabetes segment, including investments in product portfolio expansion, field force expansion, and a focus on brand expansion.
As per MD and Global CEO Umang Vohra, Cipla has always been a big player in the respiratory and acute segment but the diabetes segment remains unexplored by the company.
The segment is expected to grow faster as people age and adopt more sedentary lifestyles, with 7.7 crore Indian adults (20-79 years) diagnosed in 2021 and 4 crore undiagnosed. For the fiscal year ending April 2023, the anti-diabetes segment has a market value of Rs 16,704 crore.
Cipla chose to sign licensing agreements for patented products. It has also entered into distribution agreements with MNCs and made some acquisitions. Furthermore, the drug maker is adding more people, and refocusing its sales pitch.
Last month, Cipla cracked a perpetual license agreement with Novartis for Galvus and its combination brands. As per data released by IQVIA, it reported sales of nearly Rs 270 crore in FY23.
Additionally, the Galvus deal will pave the way for Cipla to improve its ranking from 14th position to 8th in the anti-diabetic segment.
Cipla’s efforts have gradually but steadily paid off; the company has grown 9% faster than the 6.8% market growth in the anti-diabetes segment.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.